Vinphaco Factory Tour Welcomes Sri Lanka Delegation

On January 23, 2026, Vinphaco was honored to welcome a distinguished delegation from Sri Lanka to our manufacturing facility as part of the Vinphaco Factory Tour 2026. The visit marked an important milestone in strengthening international cooperation and expanding sustainable partnerships within the global pharmaceutical industry.

As one of Vietnam’s leading pharmaceutical manufacturers, Vinphaco continues to invest in modern infrastructure, advanced technologies, and internationally recognized quality systems. This factory tour provided an opportunity for our Sri Lankan partners to gain a comprehensive understanding of our manufacturing capabilities, regulatory compliance framework, and long-term development strategy.

1. Introduction to Vinphaco’s Manufacturing Capabilities

During the visit, the delegation toured Vinphaco’s newly upgraded manufacturing facilities, which are designed and operated in full compliance with GMP standards. The tour covered key operational areas, including raw material storage, production zones, packaging lines, quality laboratories, and finished-product warehouses.

Our technical and management teams introduced the end-to-end pharmaceutical production workflow, highlighting how each process is strictly controlled to ensure safety, accuracy, and traceability. Visitors were provided with in-depth explanations of equipment qualification, environmental monitoring, validation systems, and batch documentation procedures.

2. Quality Control and Compliance Excellence

A major focus of the visit was Vinphaco’s Quality Control (QC) and Quality Assurance (QA) systems. The delegation learned how Vinphaco maintains consistent product quality through:

• Rigorous raw material testing

• In-process quality monitoring

• Stability studies and shelf-life management

• Final product release procedures

• Digital documentation and audit readiness systems

These processes demonstrate Vinphaco’s strong commitment to meeting international regulatory requirements and ensuring patient safety in every market we serve.

Quality is not merely a regulatory obligation at Vinphaco—it is a fundamental principle integrated into all operations. Continuous employee training, routine internal audits, and investment in modern laboratory technology support our long-term quality objectives.

3. Productive Discussions and Cooperation Opportunities

In addition to the factory tour, both parties participated in productive business discussions focused on strengthening cooperation in the healthcare sector. Topics included pharmaceutical product development, regulatory pathways, market registration strategies, and distribution opportunities within Sri Lanka.

The discussions highlighted a shared vision of building long-term partnerships based on transparency, technical collaboration, and mutual growth. Both sides expressed strong interest in expanding cooperation across multiple product categories in the future.

4. Strengthening Global Healthcare Partnerships

The Sri Lanka delegation’s visit reflects Vinphaco’s growing role as a trusted pharmaceutical manufacturing partner in international markets. Through consistent quality standards, regulatory compliance, and customer-focused solutions, Vinphaco continues to expand its global footprint.

This factory tour served not only as a technical introduction but also as an important platform for building trust and alignment between partners. It reinforced our mutual goal of contributing to improved access to safe, effective, and affordable healthcare products.

5. Looking Ahead

Vinphaco sincerely appreciates the Sri Lanka delegation for their visit and valuable exchange of ideas. We look forward to transforming this engagement into a strong, sustainable, and long-term partnership, supporting healthcare development in both countries.

With a clear focus on innovation, quality excellence, and international collaboration, Vinphaco remains committed to delivering reliable pharmaceutical solutions that contribute positively to global public health.